The House of Commons Health Select Committee has undertaken an inquiry on what the UK's regulatory arrangements will be after Brexit in order to ensure the safe and effective supply of medicines, medical devices, medical products and substances of human origin.
This submission has been led by Professor Alan Boyd, president of the Faculty of Pharmaceutical Medicine (FPM), on behalf of the Academy of Medical Royal Colleges’ (AoMRC) Council, and with contributions from Professor Margaret Johnson, Royal College of Physicians (RCP) academic vice president, and Professor Nicola Strickland, president of the Royal College of Radiologists (RCR).
The RCP calls on the government to ensure that the UK:
- maintains a system for rapid review and approval of novel clinical trials so that it remains a key country for the conduct of clinical research
- maintains ongoing work to develop clinicians as key investigators with the appropriate training and supports
- keeps costs for approving and delivering clinical trials in the UK competitive so companies are incentivised to come to the UK
- focuses on innovative adaptive licensing processes with a closer alignment of the regulator and health technology assessments
- considers developing a system of rapid access for medicines with a serious unmet medical need as recommended in the Life Science Industrial Strategy Review and the Accelerated Access Review
- works with the European Commission and European Medicines Agency to ensure that the UK maintains its membership of European (non-EU) public health networks.
For more information please contact Jayne Black, RCP senior policy adviser: email@example.com.